Protagonist Therapeutics Inc
$ 87.39
0.92%
24 Feb - close price
- Market Cap 5,413,231,000 USD
- Current Price $ 87.39
- High / Low $ 89.59 / 86.00
- Stock P/E 131.20
- Book Value 10.34
- EPS 0.66
- Next Earning Report 2026-03-18
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE 0.08 %
- 52 Week High 96.54
- 52 Week Low 34.81
About
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark, California.
Analyst Target Price
$101.92
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-06 | 2025-05-05 | 2025-02-25 | 2024-11-04 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-03-15 |
| Reported EPS | -0.62 | -0.55 | -0.19 | 1.98 | -0.54 | -0.5 | 3.26 | 0.44 | -0.58 | -0.68 | -0.67 | -0.69 |
| Estimated EPS | -0.63 | -0.58 | 0.11 | 0.25 | -0.6 | -0.6 | 1.19 | -0.03 | -0.69 | -0.65 | -0.73 | -0.64 |
| Surprise | 0.01 | 0.03 | -0.3 | 1.73 | 0.06 | 0.1 | 2.07 | 0.47 | 0.11 | -0.03 | 0.06 | -0.05 |
| Surprise Percentage | 1.5873% | 5.1724% | -272.7273% | 692% | 10% | 16.6667% | 173.9496% | 1566.6667% | 15.942% | -4.6154% | 8.2192% | -7.8125% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-18 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.3403 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PTGX
2026-02-24 12:53:36
Protagonist Therapeutics announced that its President and CEO, Dinesh V. Patel, Ph.D., will participate in multiple investment bank conferences throughout March 2026. The conferences include TD Cowen, Leerink Global Healthcare, Jefferies Biotech on the Beach Summit, Citizens Life Sciences, and Barclays Global Healthcare, with presentations available via webcast. The company is actively developing several novel peptide therapeutics, including icotrokinra and rusfertide, which are in advanced Phase 3 clinical development.
2026-02-24 12:53:36
Protagonist Therapeutics announced that its President and CEO, Dinesh V. Patel, Ph.D., will participate in several investment bank conferences throughout March 2026. The company, focused on peptide-based therapeutics, has two novel peptides in advanced Phase 3 clinical development and several preclinical programs. Interested parties can request meetings through their respective conference representatives, and webcasts of the presentations will be available for one year on the company's website.
2026-02-24 12:53:36
Protagonist Therapeutics (NASDAQ: PTGX) announced that CEO Dinesh V. Patel will participate in five investment bank conferences during March 2026, including events hosted by TD Cowen, Leerink, Jefferies, Citizens, and Barclays. These appearances aim to engage investors and provide updates on the company's progress, including recent NDA submissions for rusfertide and icotrokinra. Webcasts and replays of the presentations will be available for one year on the company's investor relations page.
2026-02-19 17:03:26
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has received a "Moderate Buy" consensus rating from analysts, with an average 1-year price target of $93.38. Several firms recently raised their price targets for PTGX. Despite some insider selling, institutional ownership remains high at 98.63%, and the company specializes in developing orally administered peptide-based therapies for immune-mediated diseases.
2026-02-19 00:57:36
Protagonist Therapeutics (NASDAQ:PTGX) Director Lewis Williams sold 18,000 shares of the company's stock, valued at over $1.48 million, on February 17th, reducing his stake by nearly 70%. Despite the insider sale, analysts maintain a "Moderate Buy" consensus rating with an average price target of $93.38, and the stock is trading around $82.99 with a market cap of $5.19 billion. The company is a clinical-stage biopharmaceutical firm focused on orally administered peptide-based therapies.
2026-02-19 00:00:06
Protagonist Therapeutics director Lewis T. Williams sold 18,000 shares of common stock for $1.48 million on February 17, 2026, after exercising options to acquire the same number of shares. Following these transactions, Williams directly owns 7,825 shares. The company has recently received positive analyst updates and price target increases from firms like H.C. Wainwright, Truist Securities, JPMorgan, Citizens, and Jefferies, noting progress on its lead assets, rusfertide and icotrokinra.
